En vivo
FierceBiotechAmid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plantEndpoints NewsGan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma dataFierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatmentBioWorldBiggest gainers and losers for June 8-12, 2026FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesEndpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffClinical OMICsRewriting Cancer Care Through EpigeneticsFierceBiotechTraws defers midphase flu study after negative regulatory reviewEndpoints NewsSix leaders working on LGBTQ+ inclusion in biopharmaBioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitorsBioWorldCaregen reports new GLP-1R agonists
BioWorld 27 ene 2026

Maresin 1 improves cardiac function after myocardial infarction

Maresin 1 improves cardiac function after myocardial infarction

Original
Contenido no disponible. Consulta la fuente original.